Abstract. Tubulointerstitial fibrosis is a common end point of chronic kidney diseases, and preventing its progression is key to avoiding renal failure. Transforming growth factor-β (TGF-β) and associated molecules promote tubulointerstitial fibrosis; however, effective therapies targeting these molecules have yet to be developed. Lysyl oxidase-like 2 (LOXL2), which is involved in invasive growth and metastasis of malignant neoplasms, has recently been reported to serve a key role in hepatic and pulmonary fibrosis. However, little is currently known regarding LOXL2 expression in the kidney and its involvement in tubulointerstitial fibrosis. The present study evaluated LOXL2 expression in human and mouse kidney tissues, as well as in cultured renal cells. LOXL2 protein expression was detected in glomerular capillary loops and tubular epithelial cells in human and mouse kidneys. Glomerular LOXL2 was localized to the cytoplasm of podocytes, as determined by double immunofluorescence microscopy using a podocyte marker (synaptopodin). This result was supported by western blot analysis, which demonstrated that LOXL2 protein expression is present in cultured human podocytes and HK-2 human proximal tubular cells. In addition, the mRNA and protein expression levels of LOXL2 were higher in a mouse model of tubulointerstitial fibrosis compared with in control mice. In addition, immunohistochemistry results demonstrated that LOXL2 is present in the fibrous interstitium and infiltrating mononuclear cells in a mouse model of tubulointerstitial fibrosis. The present study demonstrated that LOXL2 is expressed in compartments of renal tissue, where it appears to contribute to the progression of tubulointerstitial fibrosis.
Introduction
Tubulointerstitial fibrosis is a common end point of diabetic nephropathy, allograft rejection and various glomerulonephritides. Therefore, preventing tubulointerstitial fibrosis is an important strategy in the treatment of chronic kidney diseases.
Members of the lysyl oxidase (LOX) family [e.g., LOX and LOX-like (LOXL) [1] [2] [3] [4] are responsible for the cross-linking of collagen and elastin in the extracellular matrix through their copper-dependent amine oxidase activity. In addition, LOX family members exhibit various functions in cell proliferation, tumor invasion and metastasis, and organ development (1) . LOXL2 is the most thoroughly studied of the LOX family members. Its expression is associated with tumor cell differentiation in colon and esophageal carcinoma (2) , and proliferation, migration and invasion of human hepatocellular carcinoma cells (3) . Increased LOXL2 expression is also associated with poor survival in squamous cell carcinoma of the larynx and lung (4) , and appears to serve a role in the metastatic potential of breast (5) and gastric carcinoma (6) . Potential mechanisms underlying the effects of LOXL2 include fibroblast activation in the tumor microenvironment (7), induction of epithelial-mesenchymal transition in tumor cells (5) , and matrix remodeling via regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 (8) .
The contribution of LOXL2 to benign fibrosing diseases has been studied in several organs. Previous studies have indicated that LOXL2 expression is associated with hepatic fibrosis in Wilson's disease, primary biliary cirrhosis (9) and hepatocellular carcinoma (10) . Elevated serum LOXL2 levels are also associated with disease progression in idiopathic pulmonary fibrosis (11) , and LOXL2 upregulation is associated with scar formation following glaucoma surgery (12) .
An inhibitory monoclonal antibody to LOXL2 has been developed; AB0023 binds to human and mouse LOXL2, and AB0024 (simtuzumab) is its humanized form. The antifibrotic effects of AB0023, AB0024 and other inhibitory antibodies have been determined in several organs. For example, in a rabbit model of glaucoma surgery, AB0023 attenuated postoperative fibrosis (12) . In BALB/c mice, AB0023 attenuated tetrachloride-induced hepatic fibrosis and decreased phosphorylated-Smad3 signaling. In C57BL/6 mice, AB0023 attenuated high-dose bleomycin-induced pulmonary fibrosis, Lysyl oxidase-like 2 is expressed in kidney tissue and is associated with the progression of tubulointerstitial fibrosis Departments of 1 and this effect was mediated by inhibiting fibroblast recruitment and activation (13) . Based on the results of previous animal experiments, clinical trials of simtuzumab for human fibrosing diseases have been performed. The target diseases include advanced liver fibrosis due to human immunodeficiency virus and hepatitis C virus infection (14) , and idiopathic pulmonary fibrosis (clinicaltrials.gov/ct2/show/NCT01769196). Although fibrosis is a clinically important pathological process in kidney disease, little is currently known regarding the expression of LOXL2 in renal tissue and its contribution to the development of renal tubulointerstitial fibrosis. In the present study, the expression of LOXL2 in normal kidney was evaluated in tissues and cell lines. In addition, to evaluate its possible profibrotic role, LOXL2 expression was evaluated in the kidneys of mice following the induction of tubulointerstitial fibrosis. The podocytes were grown in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.), 10% FBS and insulin-transferrin-selenium supplement (Gibco; Thermo Fisher Scientific, Inc.) at 33˚C to activate the SV40 large T antigen. The cells were then cultured at 37˚C for 2 weeks to induce differentiation (15) , which was confirmed by western blotting for synaptopodin (data not presented).
Materials and methods

Renal
Animal model of tubulointerstitial fibrosis. Male CD1 mice of 8 weeks of age (Orient Bio, Inc., Seongnam, South Korea) were used for the animal experiments. Mice were housed at 20˚C with a 12-h light/dark cycle and free access to rodent chow and water. Tubulointerstitial fibrosis was induced in 4 mice (mean body weight, 42.5 g) by intraperitoneal injection of folic acid (240 µg/g body weight), according to previously described methods (16, 17) . The folic acid solution was prepared by dissolving folic acid powder (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) in 0.3 M NaHCO 3 . Control CD1 mice (n= 4; mean body weight, 43.1 g) were intraperitoneally injected with the same amount of vehicle (NaHCO 3 ). After 4 weeks, the mice were sacrificed, and the kidneys were harvested. Fresh frozen tissues were stored at -70˚C subsequent to instant freezing in liquid nitrogen. Additional tissues were fixed in 4% formaldehyde for 24 h at room temperature and embedded in paraffin overnight at 55-65˚C using an automatic tissue processer (EFTP-FAST 360; Intelsint, Turin, Italy). The present study was approved by the Institutional Animal Care and Use Committee of Yonsei University Health System (Seoul, South Korea).
Western blot analysis of LOXL2 expression. HK-2 cells, MDCK cells and differentiated human podocytes were lysed in radioimmunoprecipitation assay buffer (Biosesang, Inc., Seongnam, Korea) containing protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). The samples were centrifuged at 15,871 x g for 30 min at 4˚C, and protein concentration was measured using the bicinchoninic acid protein assay kit (Thermo Scientific, Inc.) according to the manufacturer's protocol. Protein samples (50 µg) were separated by 10% SDS-PAGE for 2 h at 100 V and were then transferred to a polyvinylidene fluoride membrane. After blocking with 3% skim milk for 1 h at room temperature, the membrane was incubated with the following primary antibodies overnight at 4˚C: Anti-synaptopodin (cat. no. sc-21537; 1:2,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-LOXL2 (cat. no. ab96233; 1:500; Abcam, Cambridge, MA, USA) and anti-LOXL2, which has epitope homology to canine species (cat. no. TA335061; 1:100; OriGene Technologies, Inc., Rockville, MD, USA). The membrane was then washed with Tris-buffered saline containing 0.1% Tween-20 and was incubated with horseradish peroxidase-labeled secondary antibodies (cat. no. sc-2020; 1:5,000; Santa Cruz Biotechnology, Inc.; and cat. no. K4003; 1:5,000; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) for 1 h at room temperature. Protein bands were visualized using Pierce Enhanced Chemiluminescence Western Blotting Substrate (Thermo Fisher Scientific, Inc.). After stripping the membrane with Restore Western Blot Stripping Buffer (Thermo Fisher Scientific, Inc.) for 15 min at room temperature, the membrane was incubated with an anti-β-actin antibody (cat. no. sc-47778; 1:2,000; Santa Cruz Biotechnology, Inc.), which was used as a loading control. In addition, fresh frozen kidneys from vehicle or folic acid-injected mice were homogenized, and western blotting was performed in a similar manner. Semi-quantification of the bands was performed by densitometry using Image J software (version 1.50i; National Institutes of Health, Bethesda, MD, USA).
Immunohistochemistry and immunofluorescence analysis of LOXL2 in human and mouse kidneys. LOXL2 expression in human and mouse kidneys was evaluated by immunohistochemistry and Olympus BX53 light microscope (Olympus Corporation, Tokyo, Japan). Paraffin-embedded human kidney tissues from 4 patients were obtained from the surgical pathology archive of the Department of Pathology, Yonsei University, Gangnam Severance Hospital (Seoul, South Korea). These tissues were obtained from a non-neoplastic portion of a nephrectomy specimen of a renal tumor. The use of archived human tissue was approved by the institutional review board of Yonsei University, Gangnam Severance Hospital. The paraffin-embedded kidneys from the aforementioned vehicle-and folic acid-injected mice were also used for immunohistochemical analysis of LOXL2 expression.
Human and mouse kidney tissues were cut into 4-µm sections, deparaffinized, and rehydrated using xylene and ethanol. Antigen retrieval was conducted by microwaving the tissue sections in 0.01 M sodium citrate buffer (pH 6.0) for 10 min. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxidase for 10 min. The tissue sections were then incubated overnight with a primary antibody against LOXL2 (cat. no. ab96233; 1:1,000; Abcam) at 4˚C, followed by incubation with a horseradish peroxidase-labeled secondary antibody (cat. no. K4003; prediluted; Dako; Agilent Technologies, Inc.) for 1 h at room temperature. The protein was visualized using the chromogen diaminobenzidine.
Double immunofluorescence staining for LOXL2 along with synaptopodin was performed in a similar manner. Sections were incubated with the primary antibody against LOXL2 (1:100) for 4 h at room temperature, followed by incubation with a Texas Red-conjugated anti-rabbit immunoglobulin G (cat. no. TI-1000; 1:50; Vector Laboratories, Inc., Burlingame, CA, USA) overnight at 4˚C. Subsequently, the tissue sections were incubated with a primary antibody against synaptopodin (cat. no. 65294; 1:50; Progen Biotechnik GmbH, Heidelberg, Germany) for 4 h at room temperature, followed by incubation with fluorescein isothiocyanate-conjugated anti-mouse secondary antibody (cat. no. FI-2000; 1:50; Vector Laboratories, Inc.) overnight at 4˚C.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis of LOXL2 expression.
The mRNA expression levels of LOXL2 in renal cells and fresh frozen kidneys from the vehicle-or folic acid-injected mice were analyzed by RT-qPCR. RNA was extracted using the RNeasy Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol, and the RNA was reverse transcribed using the QuantiTect Reverse Transcription kit (Qiagen GmbH) according to the manufacturer's protocol. PCR amplification was performed using TaqMan Gene Expression Master Mix and an ABI 7900 HT real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with the following thermal cycle: 2 min at 50˚C for uracil DNA-glycosylase enzyme incubation and 10 min at 95˚C for AmpiTaq Gold enzyme activation, followed by 40 cycles of 15 sec at 95˚C and 1 min at 60˚C. TaqMan primer/probes for mouse LOXL2 (cat. no. Mm00804740_m1) and ribosomal 18S RNA (cat. no. Mm03928990_g1) were purchased from Applied Biosystems (Thermo Fisher Scientific, Inc.). Expression was calculated using the 2 -ΔΔCq method (18) .
Statistical analysis. Quantitative analysis was performed for the western blotting and RT-qPCR results. Folic acid-injected and vehicle-treated control groups were compared (n=4 mice/group). Data are expressed as the mean ± standard deviation and were compared using the Mann-Whitney U test. The analyses were performed using GraphPad Prism 6 for Windows (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
LOXL2 protein expression in human and mouse kidneys.
Immunohistochemistry results demonstrated that LOXL2 protein was expressed in the glomeruli and tubular epithelial cells in human kidneys (Fig. 1A) . In the glomeruli, LOXL2 staining was observed along the outer surface of capillary loops.
In the tubular epithelial cells, LOXL2 staining was cytoplasmic with no nuclear or membranous staining observed (Fig. 1A) . Proximal and distal tubules expressed LOXL2; however, more prominent staining was detected in distal tubular epithelial cells. In the mouse kidney, LOXL2 staining was also observed in the glomeruli and tubular epithelial cells (Fig. 1B) .
To determine the precise location of LOXL2 expression, double immunofluorescence microscopy, using the podocyte marker synaptopodin, was performed in the human kidney. LOXL2 expression was detected in the cytoplasm of podocytes, where synaptopodin expression was also observed (Fig. 2) .
LOXL2 expression in cultured cells.
In cultured cell lines, LOXL2 expression was detected in human podocytes and HK-2 cells, as determined by western blot analysis, which supported the aforementioned results. However, MDCK cells, which are tubular cells derived from canine kidney, did not express LOXL2 (Fig. 3) .
LOXL2 expression in a mouse model of tubulointerstitial fibrosis.
Folic acid injection successfully induced diffuse renal tubulointerstitial fibrosis in mice (Fig. 4A and B) . Immunohistochemistry analysis of LOXL2 demonstrated strong immunoreactivity in infiltrating inflammatory cells and the interstitium, in addition to glomerular and tubular expression (Fig. 4C) . RT-qPCR analysis indicated that the mRNA expression levels of LOXL2 were significantly increased in folic acid-injected mice compared with vehicle-injected controls (P= 0.029; Fig. 4D ). In addition, as determined by western blotting, the protein expression levels of LOXL2 were increased in folic acid-injected mice compared with vehicle-injected mice (P=0.023; Fig. 4E ).
Discussion
Tubulointerstitial fibrosis occurs during the progression of all chronic kidney diseases. Preventing tubulointerstitial fibrosis, regardless of its etiology, is important in the preservation of renal function. TGF-β is a key molecule in the development and progression of tubulointerstitial fibrosis. Activators of latent TGF-β include integrin αvβ6; downstream signal transduction molecules of the TGF-β signaling pathway, such as members of the Smad family and mitogen-activated protein kinases; and upstream signal transduction molecules. Contributing signal transduction pathways and mechanisms include the Wnt/β-catenin pathway, platelet-derived growth factors, epithelial-mesenchymal transition and autophagy (19) . Recently, knowledge regarding the mechanisms underlying the pathogenesis of tubulointerstitial fibrosis has increased, and an animal study regarding its prevention has produced promising results (20) . However, few therapeutic agents for clinical use have been developed. Therefore, a better understanding of the molecular mechanisms is required for the development of novel treatment strategies for tubulointerstitial fibrosis.
LOXL2, which serves a role in cancer metastasis, is also involved in organ fibrosis. Previous studies have demonstrated the involvement of LOXL2 in hepatic and pulmonary fibrosis, and clinical trials have evaluated a LOXL2-specific inhibitor (9, (11) (12) (13) . Although the clinical implications of kidney fibrosis are substantial, little is currently known regarding LOXL2 expression in this organ, and the role of LOXL2 in tubulointerstitial fibrosis remains to be elucidated. Therefore, the present study evaluated LOXL2 expression in cellular compartments of the kidney and its possible contribution to tubulointerstitial fibrosis.
A previous study reported that LOXL2 expression in HK-2 cells was increased by hypoxia and hyperglycemia, and this alteration was associated with hypoxia inducible factor-1α (21) . The present study revealed that LOXL2 is primarily expressed in tubular cells in the kidney, particularly in distal tubular cells. There are numerous mechanisms by which tubular epithelial cells initiate or contribute to the progression of tubulointerstitial fibrosis. Following hypoxic, toxic or immunological insult-induced injury, tubular cells secrete chemoattractants to induce interstitial inflammation (22) . TGF-β1 and type III TGF-β1 receptor have critical roles in the linkage of inflammation and fibrosis via the TGF-β/Smad3 signaling pathway (23) . Epithelial-mesenchymal transition may also contribute to interstitial fibrosis by providing a source of fibrogenic myofibroblasts (24) . Tubular epithelial cells lose cell-cell adhesion and acquire myofibroblast properties through the induction of TGF-β. Other signaling pathways and cellular components, including autophagy, Wnt/β-catenin signaling and integrin-linked kinase, are also involved in this process (25, 26) . Although the underlying mechanisms remain unclear, it is highly probable that tubular epithelial cells have a critical role in the progression of tubulointerstitial fibrosis. The present observation that LOXL2 is expressed in tubular epithelial cells suggests a role for LOXL2 in TGF-β-mediated tubulointerstitial fibrosis. This hypothesis is supported by the increased LOXL2 mRNA and protein levels detected in the kidneys of mice with folic acid-induced tubulointerstitial fibrosis.
The association between LOXL2 and TGF-β has been investigated in numerous studies. Sethi et al demonstrated that the expression of LOX family genes, including LOXL2, is induced by TGF-β1, TGF-β2 and TGF-β3, and is mediated by canonical Smad signaling and noncanonical signaling pathways (27) . Voloshenyuk et al reported that TGF-β1 upregulates LOX expression in cardiac fibroblasts, and this phenomenon may be prevented by inhibiting Smad3 (28) . Conversely, an inhibitory monoclonal antibody against LOXL2 has been reported to decrease fibroblast activation and TGF-β signaling, suggesting that LOXL2 serves a role in activating TGF-β (13). Direct suppression of TGF-β was not successful in preventing renal fibrosis due to of the diversity of TGF-β isoforms and their signaling pathways (29) . Therefore, it may be suggested that LOXL2, and other molecules involved in TGF-β signaling pathways, should be considered as therapeutic targets.
The expression of LOXL2 in infiltrating inflammatory cells detected in the present study is interesting considering that infiltrating macrophages also express TGF-β (30). This finding suggested that the potential mechanisms underlying the effects of LOXL2 in tubulointerstitial fibrosis are complex.
The present study also detected LOXL2 expression in podocytes, which may have clinical significance. Considerable evidence supports the role of podocyte injury as a key factor in the pathogenesis of focal segmental glomerulosclerosis (31) (32) (33) . Podocyte detachment is also an important pathogenic mechanism in the progression of diabetic nephropathy (34), which is characterized by nodular glomerulosclerosis. Considering the profibrogenic function of LOXL2 in other organs, it is reasonable to hypothesize that podocyte LOXL2 may contribute to the progression of glomerulosclerosis.
In conclusion, LOXL2, which is a protein involved in extracellular matrix remodeling and organ fibrosis, is expressed in renal tubular epithelial cells and podocytes. Improved understanding regarding the function of LOXL2 in the kidney may strengthen knowledge of the pathophysiology of tubulointerstitial fibrosis and glomerulosclerosis, and may lead to the discovery of novel therapeutic targets.
